Trial Outcomes & Findings for Effect of a Wide Spectrum Nutritional Supplement on Mitochondrial Function in Children With Autism Spectrum Disorder (NCT NCT03835117)

NCT ID: NCT03835117

Last Updated: 2025-05-09

Results Overview

Mitochondrial activity and redox metabolism at baseline and after the placebo and supplement arms of the study, as determined through laboratory assessment. Normal Range 4.4 to 22 with Mean and SD of 12.1 and 5.1. It is better to be within the normal range than outside of the normal range regardless of whether the value is higher or lower.

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

16 participants

Primary outcome timeframe

Before (Baseline), After Part I (Week 12), After Part 2 (Week 24)

Results posted on

2025-05-09

Participant Flow

Participant milestones

Participant milestones
Measure
Wide-spectrum Nutritional Supplement First
The Wide-spectrum nutritional supplement used will be a combination of NeuroNeeds: SpectrumNeeds and QNeeds. Weight based dosing will be used. The daily serving size will be divided into two oral daily doses in the form of a powder which can be mixed into liquid or food. Together, there are 34 different dietary supplements in the products. Except for ubiquinol, all of these nutrients are provided in a powder form in SpectrumNeeds. Ubiquinol is provided separately in QNeeds gel capsules. These capsules can be swallowed whole, or cut with scissors and the contents squeezed out and added to SpectrumNeeds just before ingestion. Wide-spectrum nutritional supplement: Comprehensive powder with 33 dietary supplements and 1 dietary supplement via gel capsule.
Placebo Control First
Participants randomized to receive placebo will take placebo in an oral form divided into powder and a gel capsule in the same manner as treatment. For the second phase of the cross over, participants will be part of the opposite group they were assigned to in Phase I (Placebo or Treatment). Quantities for placebo or treatment will match across phases for each subject, utilizing the same weight based dosing. Placebo: Inactive placebo comparator
Phase I - Week 1 to Week 12
STARTED
7
9
Phase I - Week 1 to Week 12
COMPLETED
7
9
Phase I - Week 1 to Week 12
NOT COMPLETED
0
0
Phase II - Week 13- Week 24
STARTED
7
9
Phase II - Week 13- Week 24
COMPLETED
5
6
Phase II - Week 13- Week 24
NOT COMPLETED
2
3

Reasons for withdrawal

Reasons for withdrawal
Measure
Wide-spectrum Nutritional Supplement First
The Wide-spectrum nutritional supplement used will be a combination of NeuroNeeds: SpectrumNeeds and QNeeds. Weight based dosing will be used. The daily serving size will be divided into two oral daily doses in the form of a powder which can be mixed into liquid or food. Together, there are 34 different dietary supplements in the products. Except for ubiquinol, all of these nutrients are provided in a powder form in SpectrumNeeds. Ubiquinol is provided separately in QNeeds gel capsules. These capsules can be swallowed whole, or cut with scissors and the contents squeezed out and added to SpectrumNeeds just before ingestion. Wide-spectrum nutritional supplement: Comprehensive powder with 33 dietary supplements and 1 dietary supplement via gel capsule.
Placebo Control First
Participants randomized to receive placebo will take placebo in an oral form divided into powder and a gel capsule in the same manner as treatment. For the second phase of the cross over, participants will be part of the opposite group they were assigned to in Phase I (Placebo or Treatment). Quantities for placebo or treatment will match across phases for each subject, utilizing the same weight based dosing. Placebo: Inactive placebo comparator
Phase II - Week 13- Week 24
Lost to Follow-up
2
3

Baseline Characteristics

Effect of a Wide Spectrum Nutritional Supplement on Mitochondrial Function in Children With Autism Spectrum Disorder

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Wide-spectrum Nutritional Supplement First
n=7 Participants
The Wide-spectrum nutritional supplement used will be a combination of NeuroNeeds: SpectrumNeeds and QNeeds. Weight based dosing will be used. The daily serving size will be divided into two oral daily doses in the form of a powder which can be mixed into liquid or food. Together, there are 34 different dietary supplements in the products. Except for ubiquinol, all of these nutrients are provided in a powder form in SpectrumNeeds. Ubiquinol is provided separately in QNeeds gel capsules. These capsules can be swallowed whole, or cut with scissors and the contents squeezed out and added to SpectrumNeeds just before ingestion. Wide-spectrum nutritional supplement: Comprehensive powder with 33 dietary supplements and 1 dietary supplement via gel capsule.
Placebo Control First
n=9 Participants
Participants randomized to receive placebo will take placebo in an oral form divided into powder and a gel capsule in the same manner as treatment. For the second phase of the cross over, participants will be part of the opposite group they were assigned to in Phase I (Placebo or Treatment). Quantities for placebo or treatment will match across phases for each subject, utilizing the same weight based dosing. Placebo: Inactive placebo comparator
Total
n=16 Participants
Total of all reporting groups
Age, Continuous
9.7 years
STANDARD_DEVIATION 4.1 • n=99 Participants
9.0 years
STANDARD_DEVIATION 3.9 • n=107 Participants
9.3 years
STANDARD_DEVIATION 5.1 • n=206 Participants
Sex: Female, Male
Female
0 Participants
n=99 Participants
2 Participants
n=107 Participants
2 Participants
n=206 Participants
Sex: Female, Male
Male
7 Participants
n=99 Participants
7 Participants
n=107 Participants
14 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
3 Participants
n=99 Participants
3 Participants
n=107 Participants
6 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
4 Participants
n=99 Participants
6 Participants
n=107 Participants
10 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Asian
1 Participants
n=99 Participants
2 Participants
n=107 Participants
3 Participants
n=206 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Black or African American
1 Participants
n=99 Participants
0 Participants
n=107 Participants
1 Participants
n=206 Participants
Race (NIH/OMB)
White
5 Participants
n=99 Participants
7 Participants
n=107 Participants
12 Participants
n=206 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=99 Participants
0 Participants
n=107 Participants
0 Participants
n=206 Participants
Region of Enrollment
United States
7 participants
n=99 Participants
9 participants
n=107 Participants
16 participants
n=206 Participants

PRIMARY outcome

Timeframe: Before (Baseline), After Part I (Week 12), After Part 2 (Week 24)

Population: Results are for Placebo and Treatment arm. Flow is for which treatment given first.

Mitochondrial activity and redox metabolism at baseline and after the placebo and supplement arms of the study, as determined through laboratory assessment. Normal Range 4.4 to 22 with Mean and SD of 12.1 and 5.1. It is better to be within the normal range than outside of the normal range regardless of whether the value is higher or lower.

Outcome measures

Outcome measures
Measure
Wide-spectrum Nutritional Supplement
n=16 Participants
The Wide-spectrum nutritional supplement used will be a combination of NeuroNeeds: SpectrumNeeds and QNeeds. Weight based dosing will be used. The daily serving size will be divided into two oral daily doses in the form of a powder which can be mixed into liquid or food. Together, there are 34 different dietary supplements in the products. Except for ubiquinol, all of these nutrients are provided in a powder form in SpectrumNeeds. Ubiquinol is provided separately in QNeeds gel capsules. These capsules can be swallowed whole, or cut with scissors and the contents squeezed out and added to SpectrumNeeds just before ingestion. Wide-spectrum nutritional supplement: Comprehensive powder with 33 dietary supplements and 1 dietary supplement via gel capsule.
Placebo Control
n=16 Participants
Participants randomized to receive placebo will take placebo in an oral form divided into powder and a gel capsule in the same manner as treatment. For the second phase of the cross over, participants will be part of the opposite group they were assigned to in Phase I (Placebo or Treatment). Quantities for placebo or treatment will match across phases for each subject, utilizing the same weight based dosing. Placebo: Inactive placebo comparator
Change in Mitochondrial Activity in Study Patients: Citrate Synthase
Before
40.56 nmoles/min/mg protein
Standard Deviation 16.64
29.09 nmoles/min/mg protein
Standard Deviation 11.48
Change in Mitochondrial Activity in Study Patients: Citrate Synthase
After
27.41 nmoles/min/mg protein
Standard Deviation 6.43
37.78 nmoles/min/mg protein
Standard Deviation 16.89

PRIMARY outcome

Timeframe: Before (Baseline), After Part I (Week 12), After Part 2 (Week 24)

Population: Results are for Placebo and Treatment arm. Flow is for which treatment given first.

Mitochondrial activity and redox metabolism at baseline and after the placebo and supplement arms of the study, as determined through laboratory assessment. Normal range is 3.4 to 11.9 with a mean of 7.65. Outside of the normal range is worse regardless of whether it is above or below the normal range.

Outcome measures

Outcome measures
Measure
Wide-spectrum Nutritional Supplement
n=16 Participants
The Wide-spectrum nutritional supplement used will be a combination of NeuroNeeds: SpectrumNeeds and QNeeds. Weight based dosing will be used. The daily serving size will be divided into two oral daily doses in the form of a powder which can be mixed into liquid or food. Together, there are 34 different dietary supplements in the products. Except for ubiquinol, all of these nutrients are provided in a powder form in SpectrumNeeds. Ubiquinol is provided separately in QNeeds gel capsules. These capsules can be swallowed whole, or cut with scissors and the contents squeezed out and added to SpectrumNeeds just before ingestion. Wide-spectrum nutritional supplement: Comprehensive powder with 33 dietary supplements and 1 dietary supplement via gel capsule.
Placebo Control
n=16 Participants
Participants randomized to receive placebo will take placebo in an oral form divided into powder and a gel capsule in the same manner as treatment. For the second phase of the cross over, participants will be part of the opposite group they were assigned to in Phase I (Placebo or Treatment). Quantities for placebo or treatment will match across phases for each subject, utilizing the same weight based dosing. Placebo: Inactive placebo comparator
Change in Mitochondrial Activity in Study Patients: Complex I
Before
2.88 Ratio of Complex I to Citrate Synthase
Standard Deviation 1.37
3.31 Ratio of Complex I to Citrate Synthase
Standard Deviation 1.99
Change in Mitochondrial Activity in Study Patients: Complex I
After
2.98 Ratio of Complex I to Citrate Synthase
Standard Deviation 1.65
2.86 Ratio of Complex I to Citrate Synthase
Standard Deviation 0.93

PRIMARY outcome

Timeframe: Before (Baseline), After Part I (Week 12), After Part 2 (Week 24)

Population: Results are for Placebo and Treatment arm. Flow is for which treatment given first.

Mitochondrial activity and redox metabolism at baseline and after the placebo and supplement arms of the study, as determined through laboratory assessment. Normal Range (mean ±SD) 0.03 -- 0.35 (0.194 ±0.08). It is better to be within the normal range regardless of whether the value is above or below the normal range

Outcome measures

Outcome measures
Measure
Wide-spectrum Nutritional Supplement
n=16 Participants
The Wide-spectrum nutritional supplement used will be a combination of NeuroNeeds: SpectrumNeeds and QNeeds. Weight based dosing will be used. The daily serving size will be divided into two oral daily doses in the form of a powder which can be mixed into liquid or food. Together, there are 34 different dietary supplements in the products. Except for ubiquinol, all of these nutrients are provided in a powder form in SpectrumNeeds. Ubiquinol is provided separately in QNeeds gel capsules. These capsules can be swallowed whole, or cut with scissors and the contents squeezed out and added to SpectrumNeeds just before ingestion. Wide-spectrum nutritional supplement: Comprehensive powder with 33 dietary supplements and 1 dietary supplement via gel capsule.
Placebo Control
n=16 Participants
Participants randomized to receive placebo will take placebo in an oral form divided into powder and a gel capsule in the same manner as treatment. For the second phase of the cross over, participants will be part of the opposite group they were assigned to in Phase I (Placebo or Treatment). Quantities for placebo or treatment will match across phases for each subject, utilizing the same weight based dosing. Placebo: Inactive placebo comparator
Change in Mitochondrial Activity in Study Patients: Complex II
Before
0.10 Ratio of Complex II to Citrate Synthase
Standard Deviation 0.06
0.09 Ratio of Complex II to Citrate Synthase
Standard Deviation 0.05
Change in Mitochondrial Activity in Study Patients: Complex II
After
0.09 Ratio of Complex II to Citrate Synthase
Standard Deviation 0.06
0.09 Ratio of Complex II to Citrate Synthase
Standard Deviation 0.06

PRIMARY outcome

Timeframe: Before (Baseline), After Part I (Week 12), After Part 2 (Week 24)

Population: Results are for Placebo and Treatment arm. Flow is for which treatment given first.

Mitochondrial activity and redox metabolism at baseline and after the placebo and supplement arms of the study, as determined through laboratory assessment. Normal Range (mean ±SD) 0.15 -- 0.6 (0.31 ±0.1). Better scores are inside the normal range regardless of if they are higher or lower.

Outcome measures

Outcome measures
Measure
Wide-spectrum Nutritional Supplement
n=16 Participants
The Wide-spectrum nutritional supplement used will be a combination of NeuroNeeds: SpectrumNeeds and QNeeds. Weight based dosing will be used. The daily serving size will be divided into two oral daily doses in the form of a powder which can be mixed into liquid or food. Together, there are 34 different dietary supplements in the products. Except for ubiquinol, all of these nutrients are provided in a powder form in SpectrumNeeds. Ubiquinol is provided separately in QNeeds gel capsules. These capsules can be swallowed whole, or cut with scissors and the contents squeezed out and added to SpectrumNeeds just before ingestion. Wide-spectrum nutritional supplement: Comprehensive powder with 33 dietary supplements and 1 dietary supplement via gel capsule.
Placebo Control
n=16 Participants
Participants randomized to receive placebo will take placebo in an oral form divided into powder and a gel capsule in the same manner as treatment. For the second phase of the cross over, participants will be part of the opposite group they were assigned to in Phase I (Placebo or Treatment). Quantities for placebo or treatment will match across phases for each subject, utilizing the same weight based dosing. Placebo: Inactive placebo comparator
Change in Mitochondrial Activity in Study Patients: Complex IV
Before
0.18 Ratio of Complex IV to Citrate Synthase
Standard Deviation 0.04
0.21 Ratio of Complex IV to Citrate Synthase
Standard Deviation 0.07
Change in Mitochondrial Activity in Study Patients: Complex IV
After
0.22 Ratio of Complex IV to Citrate Synthase
Standard Deviation 0.04
0.17 Ratio of Complex IV to Citrate Synthase
Standard Deviation 0.03

SECONDARY outcome

Timeframe: Before (Baseline), After Part I (Week 12), After Part 2 (Week 24)

The Childhood Autism Rating Scale is a 15-item clinician-rated scale that measures the severity of core ASD symptoms of social communication and restricted and repetitive patterns of behavior, interests, or activities. Each item is scored on a 4 point scale of severity from 1 (None/Minimal) to 4 (Severe). Minimal score is 15 and maximal score is 60. The measure is the total score of the 15 items in which a score of 15-27.5 reflects minimal to no severity of symptoms, 28-33.5 reflects mild to moderate severity of symptoms, and a score of 34 or higher reflects severe symptoms. Lower scores are better.

Outcome measures

Outcome measures
Measure
Wide-spectrum Nutritional Supplement
n=16 Participants
The Wide-spectrum nutritional supplement used will be a combination of NeuroNeeds: SpectrumNeeds and QNeeds. Weight based dosing will be used. The daily serving size will be divided into two oral daily doses in the form of a powder which can be mixed into liquid or food. Together, there are 34 different dietary supplements in the products. Except for ubiquinol, all of these nutrients are provided in a powder form in SpectrumNeeds. Ubiquinol is provided separately in QNeeds gel capsules. These capsules can be swallowed whole, or cut with scissors and the contents squeezed out and added to SpectrumNeeds just before ingestion. Wide-spectrum nutritional supplement: Comprehensive powder with 33 dietary supplements and 1 dietary supplement via gel capsule.
Placebo Control
n=16 Participants
Participants randomized to receive placebo will take placebo in an oral form divided into powder and a gel capsule in the same manner as treatment. For the second phase of the cross over, participants will be part of the opposite group they were assigned to in Phase I (Placebo or Treatment). Quantities for placebo or treatment will match across phases for each subject, utilizing the same weight based dosing. Placebo: Inactive placebo comparator
Change in the Childhood Autism Rating Scale (CARS) Score
Before
34.2 CARS Scale Units
Standard Deviation 9.9
37.2 CARS Scale Units
Standard Deviation 6.8
Change in the Childhood Autism Rating Scale (CARS) Score
After
30.8 CARS Scale Units
Standard Deviation 10.7
32.2 CARS Scale Units
Standard Deviation 3.4

SECONDARY outcome

Timeframe: Before (Baseline), After Part I (Week 12), After Part 2 (Week 24)

The Clinical Global Impression - Severity scale (CGI-S) is a clinician rated 7-point measure of overall symptomatic severity of psychopathology. Scores range from 1 (Normal, not at all ill) through 4 (Moderately ill) to 7 (Among the most extremely ill patients). Lower scores are better.

Outcome measures

Outcome measures
Measure
Wide-spectrum Nutritional Supplement
n=16 Participants
The Wide-spectrum nutritional supplement used will be a combination of NeuroNeeds: SpectrumNeeds and QNeeds. Weight based dosing will be used. The daily serving size will be divided into two oral daily doses in the form of a powder which can be mixed into liquid or food. Together, there are 34 different dietary supplements in the products. Except for ubiquinol, all of these nutrients are provided in a powder form in SpectrumNeeds. Ubiquinol is provided separately in QNeeds gel capsules. These capsules can be swallowed whole, or cut with scissors and the contents squeezed out and added to SpectrumNeeds just before ingestion. Wide-spectrum nutritional supplement: Comprehensive powder with 33 dietary supplements and 1 dietary supplement via gel capsule.
Placebo Control
n=16 Participants
Participants randomized to receive placebo will take placebo in an oral form divided into powder and a gel capsule in the same manner as treatment. For the second phase of the cross over, participants will be part of the opposite group they were assigned to in Phase I (Placebo or Treatment). Quantities for placebo or treatment will match across phases for each subject, utilizing the same weight based dosing. Placebo: Inactive placebo comparator
Change in the Clinical Global Impression Scale (CGI) Score
Before
4.5 Raw Score
Standard Deviation 1.3
4.69 Raw Score
Standard Deviation 1.1
Change in the Clinical Global Impression Scale (CGI) Score
After
4.31 Raw Score
Standard Deviation 1.4
4.31 Raw Score
Standard Deviation 1.1

SECONDARY outcome

Timeframe: Before (Baseline), After Part I (Week 12), After Part 2 (Week 24)

The Children's Yale-Brown Obsessive Compulsive Scale modified for Autism Spectrum Disorder is a 5-item clinician-rated measure to evaluate severity of repetitive behavior in children with ASD. Each item is scored on a 5 point scale from 0 (None) to 4 (Extreme) for the severity of: Time Spent, Interference in everyday life, Distress, Resistance, and Degree of Control over the behavior. A total score ranges from 0 to 20. Lower scores are better.

Outcome measures

Outcome measures
Measure
Wide-spectrum Nutritional Supplement
n=16 Participants
The Wide-spectrum nutritional supplement used will be a combination of NeuroNeeds: SpectrumNeeds and QNeeds. Weight based dosing will be used. The daily serving size will be divided into two oral daily doses in the form of a powder which can be mixed into liquid or food. Together, there are 34 different dietary supplements in the products. Except for ubiquinol, all of these nutrients are provided in a powder form in SpectrumNeeds. Ubiquinol is provided separately in QNeeds gel capsules. These capsules can be swallowed whole, or cut with scissors and the contents squeezed out and added to SpectrumNeeds just before ingestion. Wide-spectrum nutritional supplement: Comprehensive powder with 33 dietary supplements and 1 dietary supplement via gel capsule.
Placebo Control
n=16 Participants
Participants randomized to receive placebo will take placebo in an oral form divided into powder and a gel capsule in the same manner as treatment. For the second phase of the cross over, participants will be part of the opposite group they were assigned to in Phase I (Placebo or Treatment). Quantities for placebo or treatment will match across phases for each subject, utilizing the same weight based dosing. Placebo: Inactive placebo comparator
Change in the Children's Yale-Brown Obsessive Compulsive Scale Modified for Autism Spectrum Disorder (CYBOCS-ASD) Score
Before
12.5 Raw Score
Standard Deviation 2.5
12.9 Raw Score
Standard Deviation 2.4
Change in the Children's Yale-Brown Obsessive Compulsive Scale Modified for Autism Spectrum Disorder (CYBOCS-ASD) Score
After
11.3 Raw Score
Standard Deviation 2.3
11.9 Raw Score
Standard Deviation 2.3

SECONDARY outcome

Timeframe: Before (Baseline), After Part I (Week 12), After Part 2 (Week 24)

The Aberrant Behavior Checklist is a 58-item caregiver questionnaire consisting of five subscales: hyperactivity, irritability, social withdrawal, stereotypic behavior and inappropriate speech in children with developmental disabilities. A higher score indicates more frequent aberrant behaviors. Our secondary measures are the subscale scores for Irritability (15 item), Social Withdrawal (16 item) and Hyperactivity (16 item). Each item rates behavior severity on a 4 point scale from 0 (Not at all a problem) to 3 (The problem is severe in degree). Total score ranges from 0 to 174. Lower scores are better.

Outcome measures

Outcome measures
Measure
Wide-spectrum Nutritional Supplement
n=16 Participants
The Wide-spectrum nutritional supplement used will be a combination of NeuroNeeds: SpectrumNeeds and QNeeds. Weight based dosing will be used. The daily serving size will be divided into two oral daily doses in the form of a powder which can be mixed into liquid or food. Together, there are 34 different dietary supplements in the products. Except for ubiquinol, all of these nutrients are provided in a powder form in SpectrumNeeds. Ubiquinol is provided separately in QNeeds gel capsules. These capsules can be swallowed whole, or cut with scissors and the contents squeezed out and added to SpectrumNeeds just before ingestion. Wide-spectrum nutritional supplement: Comprehensive powder with 33 dietary supplements and 1 dietary supplement via gel capsule.
Placebo Control
n=16 Participants
Participants randomized to receive placebo will take placebo in an oral form divided into powder and a gel capsule in the same manner as treatment. For the second phase of the cross over, participants will be part of the opposite group they were assigned to in Phase I (Placebo or Treatment). Quantities for placebo or treatment will match across phases for each subject, utilizing the same weight based dosing. Placebo: Inactive placebo comparator
Change in the Aberrant Behavior Checklist (ABC) Scores
Before
77.136 Raw Score
Standard Deviation 6.964
79.859 Raw Score
Standard Deviation 6.964
Change in the Aberrant Behavior Checklist (ABC) Scores
After
57.293 Raw Score
Standard Deviation 6.964
73.87 Raw Score
Standard Deviation 6.964

SECONDARY outcome

Timeframe: Before (Baseline), After Part I (Week 12), After Part 2 (Week 24)

The Parent-rated Anxiety Scale for Autism Spectrum Disorder is a 25-item scale that measures anxiety in youth with ASD. Each item rates the severity of a behavior on a 4 point scale from 0 (None/not present) to 3 (Severe/Very frequent and a major problem). The total score ranges from 0 to 75. Lower scores are better.

Outcome measures

Outcome measures
Measure
Wide-spectrum Nutritional Supplement
n=16 Participants
The Wide-spectrum nutritional supplement used will be a combination of NeuroNeeds: SpectrumNeeds and QNeeds. Weight based dosing will be used. The daily serving size will be divided into two oral daily doses in the form of a powder which can be mixed into liquid or food. Together, there are 34 different dietary supplements in the products. Except for ubiquinol, all of these nutrients are provided in a powder form in SpectrumNeeds. Ubiquinol is provided separately in QNeeds gel capsules. These capsules can be swallowed whole, or cut with scissors and the contents squeezed out and added to SpectrumNeeds just before ingestion. Wide-spectrum nutritional supplement: Comprehensive powder with 33 dietary supplements and 1 dietary supplement via gel capsule.
Placebo Control
n=16 Participants
Participants randomized to receive placebo will take placebo in an oral form divided into powder and a gel capsule in the same manner as treatment. For the second phase of the cross over, participants will be part of the opposite group they were assigned to in Phase I (Placebo or Treatment). Quantities for placebo or treatment will match across phases for each subject, utilizing the same weight based dosing. Placebo: Inactive placebo comparator
Change in the Parent-rated Anxiety Scale for ASD (PRAS-ASD) Score
Before
30.25 Raw Score
Standard Deviation 6.61
23.18 Raw Score
Standard Deviation 6.61
Change in the Parent-rated Anxiety Scale for ASD (PRAS-ASD) Score
After
14.625 Raw Score
Standard Deviation 6.61
26.1 Raw Score
Standard Deviation 6.61

SECONDARY outcome

Timeframe: Before (Baseline), After Part I (Week 12), After Part 2 (Week 24)

The Caregiver Strain short-form questionnaire is a 7-item measure of self-reported strain experienced by caregivers of children with behavioral disorders. Each item rates the severity of interference in the quality of the caregiver's life on a 5 point scale from 0 (Not at All) to 4 (Very Much). The scale ranges from 0 to 28. Lower scores are better.

Outcome measures

Outcome measures
Measure
Wide-spectrum Nutritional Supplement
n=16 Participants
The Wide-spectrum nutritional supplement used will be a combination of NeuroNeeds: SpectrumNeeds and QNeeds. Weight based dosing will be used. The daily serving size will be divided into two oral daily doses in the form of a powder which can be mixed into liquid or food. Together, there are 34 different dietary supplements in the products. Except for ubiquinol, all of these nutrients are provided in a powder form in SpectrumNeeds. Ubiquinol is provided separately in QNeeds gel capsules. These capsules can be swallowed whole, or cut with scissors and the contents squeezed out and added to SpectrumNeeds just before ingestion. Wide-spectrum nutritional supplement: Comprehensive powder with 33 dietary supplements and 1 dietary supplement via gel capsule.
Placebo Control
n=16 Participants
Participants randomized to receive placebo will take placebo in an oral form divided into powder and a gel capsule in the same manner as treatment. For the second phase of the cross over, participants will be part of the opposite group they were assigned to in Phase I (Placebo or Treatment). Quantities for placebo or treatment will match across phases for each subject, utilizing the same weight based dosing. Placebo: Inactive placebo comparator
Change in the Caregiver Strain Questionnaire (CGSQ) Score
Before
18.25 Raw Score
Standard Deviation 2.695
17.625 Raw Score
Standard Deviation 2.695
Change in the Caregiver Strain Questionnaire (CGSQ) Score
After
11.5 Raw Score
Standard Deviation 2.695
14.93 Raw Score
Standard Deviation 2.695

SECONDARY outcome

Timeframe: Before (Baseline), After Part I (Week 12), After Part 2 (Week 24)

The Vineland III Caregiver is a 381-item parent-reported measure of adaptive behavior in children with developmental and intellectual disabilities. The Vineland is comprised of three sub scores for the following domains: Communication, Daily Living Skills, and Socialization. The frequency of adaptive behaviors for each item is scored on a scale from 0 (Never) to 2 (Usually). The total adaptive score is reflected as a composite score of the sub domains (which is determined by age norms) in which a higher total score reflects higher functioning. The scale is standardized with a mean of 100 and standard deviation of 15.

Outcome measures

Outcome measures
Measure
Wide-spectrum Nutritional Supplement
n=16 Participants
The Wide-spectrum nutritional supplement used will be a combination of NeuroNeeds: SpectrumNeeds and QNeeds. Weight based dosing will be used. The daily serving size will be divided into two oral daily doses in the form of a powder which can be mixed into liquid or food. Together, there are 34 different dietary supplements in the products. Except for ubiquinol, all of these nutrients are provided in a powder form in SpectrumNeeds. Ubiquinol is provided separately in QNeeds gel capsules. These capsules can be swallowed whole, or cut with scissors and the contents squeezed out and added to SpectrumNeeds just before ingestion. Wide-spectrum nutritional supplement: Comprehensive powder with 33 dietary supplements and 1 dietary supplement via gel capsule.
Placebo Control
n=16 Participants
Participants randomized to receive placebo will take placebo in an oral form divided into powder and a gel capsule in the same manner as treatment. For the second phase of the cross over, participants will be part of the opposite group they were assigned to in Phase I (Placebo or Treatment). Quantities for placebo or treatment will match across phases for each subject, utilizing the same weight based dosing. Placebo: Inactive placebo comparator
Change in the Vineland III Caregiver Score
Before
62.645 Scaled Score
Standard Deviation 2.278
65.199 Scaled Score
Standard Deviation 2.278
Change in the Vineland III Caregiver Score
After
69.861 Scaled Score
Standard Deviation 2.278
62.175 Scaled Score
Standard Deviation 2.278

SECONDARY outcome

Timeframe: Screening, Baseline, After Week 4, After Week 8, After Week 12, Atter Week 16, After Week 20, After Week 24

Columbia-Suicide Severity Rating Scale: a suicide risk assessment that identifies presence and severity of suicidal ideation, planning, and behavior, as well as non-suicidal self-harm behaviors. Presence of any of these behaviors during the course of study enrollment will be considered an adverse event.

Outcome measures

Outcome measures
Measure
Wide-spectrum Nutritional Supplement
n=16 Participants
The Wide-spectrum nutritional supplement used will be a combination of NeuroNeeds: SpectrumNeeds and QNeeds. Weight based dosing will be used. The daily serving size will be divided into two oral daily doses in the form of a powder which can be mixed into liquid or food. Together, there are 34 different dietary supplements in the products. Except for ubiquinol, all of these nutrients are provided in a powder form in SpectrumNeeds. Ubiquinol is provided separately in QNeeds gel capsules. These capsules can be swallowed whole, or cut with scissors and the contents squeezed out and added to SpectrumNeeds just before ingestion. Wide-spectrum nutritional supplement: Comprehensive powder with 33 dietary supplements and 1 dietary supplement via gel capsule.
Placebo Control
n=16 Participants
Participants randomized to receive placebo will take placebo in an oral form divided into powder and a gel capsule in the same manner as treatment. For the second phase of the cross over, participants will be part of the opposite group they were assigned to in Phase I (Placebo or Treatment). Quantities for placebo or treatment will match across phases for each subject, utilizing the same weight based dosing. Placebo: Inactive placebo comparator
Evaluate Intervention Safety
0 Participants
0 Participants

SECONDARY outcome

Timeframe: Before (Baseline), After Part I (Week 12), After Part 2 (Week 24)

Differential Abilities Scale-II: cognitive abilities across core domains: verbal, nonverbal, spatial. Subtests: Verbal comprehension: 42-item domain, raw score 0-23. Naming vocabulary: 34-item domain, raw score 0-28. Word definitions: 35-item domain, raw score 0-25. Verbal similarities: 33-item domain, raw score 0-28. Picture similarities: 32-item domain, raw score 0-23. Picture similarities: 50-item domain, raw score 0-34. Matrices: 56-item domain, raw score 0-33. Pattern construction: 35-item domain, raw score 0-74. Copying: 20-item domain, raw score 0-36. Recall of designs: 22-item domain, raw score 0-43. All subdomains have a t-score range of 10-90. Verbal ability standard score ranges from 30-170. Nonverbal ability standard score ranges from 32-170. Spatial ability standard score ranges from 34-170. Total General Conceptual Ability standard score ranges from 30-170. Subtests and item sets given vary by participant age. Higher scores are better.

Outcome measures

Outcome measures
Measure
Wide-spectrum Nutritional Supplement
n=16 Participants
The Wide-spectrum nutritional supplement used will be a combination of NeuroNeeds: SpectrumNeeds and QNeeds. Weight based dosing will be used. The daily serving size will be divided into two oral daily doses in the form of a powder which can be mixed into liquid or food. Together, there are 34 different dietary supplements in the products. Except for ubiquinol, all of these nutrients are provided in a powder form in SpectrumNeeds. Ubiquinol is provided separately in QNeeds gel capsules. These capsules can be swallowed whole, or cut with scissors and the contents squeezed out and added to SpectrumNeeds just before ingestion. Wide-spectrum nutritional supplement: Comprehensive powder with 33 dietary supplements and 1 dietary supplement via gel capsule.
Placebo Control
n=16 Participants
Participants randomized to receive placebo will take placebo in an oral form divided into powder and a gel capsule in the same manner as treatment. For the second phase of the cross over, participants will be part of the opposite group they were assigned to in Phase I (Placebo or Treatment). Quantities for placebo or treatment will match across phases for each subject, utilizing the same weight based dosing. Placebo: Inactive placebo comparator
Examine the Change in Cognitive Ability
Before
73.627 Scaled Score
Standard Deviation 5.177
65.488 Scaled Score
Standard Deviation 5.177
Examine the Change in Cognitive Ability
After
76.764 Scaled Score
Standard Deviation 5.177
74.143 Scaled Score
Standard Deviation 5.177

Adverse Events

Wide-spectrum Nutritional Supplement

Serious events: 0 serious events
Other events: 1 other events
Deaths: 0 deaths

Placebo Control

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
Wide-spectrum Nutritional Supplement
n=16 participants at risk
The Wide-spectrum nutritional supplement used will be a combination of NeuroNeeds: SpectrumNeeds and QNeeds. Weight based dosing will be used. The daily serving size will be divided into two oral daily doses in the form of a powder which can be mixed into liquid or food. Together, there are 34 different dietary supplements in the products. Except for ubiquinol, all of these nutrients are provided in a powder form in SpectrumNeeds. Ubiquinol is provided separately in QNeeds gel capsules. These capsules can be swallowed whole, or cut with scissors and the contents squeezed out and added to SpectrumNeeds just before ingestion. Wide-spectrum nutritional supplement: Comprehensive powder with 33 dietary supplements and 1 dietary supplement via gel capsule.
Placebo Control
n=16 participants at risk
Participants randomized to receive placebo will take placebo in an oral form divided into powder and a gel capsule in the same manner as treatment. For the second phase of the cross over, participants will be part of the opposite group they were assigned to in Phase I (Placebo or Treatment). Quantities for placebo or treatment will match across phases for each subject, utilizing the same weight based dosing. Placebo: Inactive placebo comparator
Gastrointestinal disorders
Mild transient constipation, diarrhea, and acid reflux
6.2%
1/16 • Number of events 1 • 24 weeks
0.00%
0/16 • 24 weeks

Additional Information

Richard E Frye

Autism Discovery & Treatment Foundation

Phone: 844-ADTF-Research

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place